Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00140803|
Recruitment Status : Completed
First Posted : September 1, 2005
Last Update Posted : July 12, 2007
|Condition or disease||Intervention/treatment||Phase|
|Age-Related Macular Degeneration||Drug: Visudyne Drug: Kenalog||Phase 2|
Manhattan Eye, Ear & Throat Hospital has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.
This is a randomized, single-masked (VA examiners, angiographic graders), multi-center, Phase 2 study with 3 arms comparing VISUDYNE therapy in combination with intravitreal injection of either a 1 mg or 4 mg of triamcinolone with VISUDYNE therapy without intravitreal triamcinolone in a 1:1:1 ratio.
Re-treatment may be administered at 3 month intervals ( 14 days) if evidence of CNV leakage is detected by fluorescein angiography.
At baseline and at 3 month (+ 14 days) intervals patients will undergo the following assessments: ophthalmic examination, best corrected visual acuity, fluorescein angiography, and color fundus photography. The eligibility criteria for inclusion into the study and re-treatment of patients will be based on fluorescein angiography. Patients receiving treatment at day-1, week-3, and week-6 following the treatment will have best corrected ETDRS visual acuity testing and ophthalmic. Those patients not being re-treated will have will have best corrected ETDRS visual acuity testing and ophthalmic examination at week-6 following the re-treatment evaluation visit.
Adverse events will be assessed throughout the study.
Expected time for recruitment is 6 months; all patients will be followed for the period of 12 months in the study
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||106 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Randomized, Single-Masked, Multi-Center, Phase 2 Evaluation Of The Effect Of PDT Using Visudyne In Combination With Intravitreal Injection Of Either 0 mg, 1mg or 4mg of Kenalog In Subfoveal Occult & Minimally Classic CNV Secondary To ARMD|
|Study Start Date :||October 2003|
|Study Completion Date :||January 2007|
- The primary objective of this study is to determine the effect of Visudyne therapy in combination with 4 mg intravitreal triamcinolone on the mean change in BCVA at Month 12. [ Time Frame: 12 months ]
- • Proportion of patients having a 15 letter (3 lines) loss or more in BCVA [ Time Frame: 12 months ]
- • Proportion of patients having a 15 letter (3 lines) improvement or more in BCVA [ Time Frame: 12 months ]
- • Proportion of patients requiring re-treatment at any time during the study [ Time Frame: 12 months ]
- • The number of re-treatments required [ Time Frame: 12 months ]
- • Difference in treatment effect between 1 mg and 4 mg of triamcinolone acetonide [ Time Frame: 12 months ]
- • The change in MNREAD score [ Time Frame: 12 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00140803
|United States, New York|
|Manhattan Eye, Ear & Throat Hospital|
|New York, New York, United States, 10021|
|Canada, British Columbia|
|Vh/UBC Eye Care Centre|
|Vancouver, British Columbia, Canada, V5Z 3N9|
|Principal Investigator:||Richard F. Spaide, MD||Manhattan Eye, Ear & Throat Hospital|